Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
- Revenue in EUR (TTM)3.04bn
- Net income in EUR1.29bn
- Incorporated2008
- Employees1.60k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qiagen NV | 1.76bn | 358.03m | 8.92bn | 5.65k | 25.73 | 2.94 | 17.11 | 5.06 | 1.68 | 1.68 | 8.26 | 14.70 | 0.3488 | 2.66 | 5.45 | 311,492.70 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| Eurofins Scientific SE | 7.30bn | 475.00m | 11.92bn | 65.00k | 25.77 | 2.56 | 10.81 | 1.63 | 2.54 | 2.54 | 38.86 | 25.54 | 0.6671 | 40.83 | 5.17 | -- | 4.32 | 6.78 | 5.48 | 8.46 | 21.40 | 23.08 | 6.48 | 10.10 | 1.03 | 6.34 | 0.492 | 21.89 | 4.96 | 6.05 | -25.14 | -6.70 | 8.60 | 1.15 |
| Genmab A/S | 3.02bn | 1.25bn | 16.38bn | 2.68k | 12.88 | 3.24 | 12.56 | 5.43 | 147.88 | 147.88 | 357.69 | 587.89 | 0.5535 | 16.68 | 3.60 | 8,407,228.00 | 22.89 | 17.70 | 25.72 | 19.07 | 94.27 | -- | 41.35 | 35.77 | 6.01 | -- | 0.0241 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
| Lonza Group AG | 7.17bn | 997.72m | 40.16bn | 19.77k | 40.26 | 3.92 | 23.51 | 5.60 | 12.94 | 13.51 | 93.02 | 133.07 | 0.3375 | 2.45 | 4.32 | 330,332.30 | 4.70 | 4.70 | 5.78 | 5.72 | 36.15 | 37.28 | 13.92 | 13.02 | 1.77 | 7.77 | 0.313 | 34.17 | -0.6541 | 7.70 | 42.92 | 4.48 | 7.13 | 10.76 |
| argenx SE | 3.04bn | 1.29bn | 43.87bn | 1.60k | 36.38 | -- | -- | 14.44 | 19.48 | 19.48 | 45.96 | -- | -- | -- | -- | 1,899,643.00 | -- | -7.11 | -- | -7.96 | 89.63 | -- | 42.54 | -27.22 | -- | -- | -- | -- | 78.60 | 94.61 | 382.34 | -- | 7.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 2.29m | 3.71% |
| Wellington Management Co. LLPas of 24 Jun 2024 | 1.82m | 2.96% |
| Norges Bank Investment Managementas of 06 Jan 2026 | 1.74m | 2.83% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 1.21m | 1.96% |
| BlackRock Advisors (UK) Ltd.as of 09 Jan 2026 | 956.26k | 1.55% |
| Amundi Asset Management SASU (Investment Management)as of 30 Jan 2026 | 845.69k | 1.37% |
| Geode Capital Management LLCas of 05 Feb 2026 | 707.87k | 1.15% |
| Schroder Investment Management Ltd.as of 31 Dec 2025 | 561.10k | 0.91% |
| Bellevue Asset Management AGas of 31 Dec 2025 | 544.45k | 0.88% |
| Fidelity Management & Research Co. LLCas of 08 Jan 2026 | 437.95k | 0.71% |
